Current Report Filing (8-k)
July 09 2018 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 8, 2018
ARDELYX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36485
|
|
26-1303944
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
34175 Ardenwood Blvd., Suite 200
Fremont, CA 94555
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code:
(510) 745-1700
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
|
Ardelyx, Inc. (the Company) announced that Reginald Seeto, MBBS, currently the Companys Chief Operating Officer, will transition from his
current position with the Company effective August 3, 2018, after which time, the Company expects that Dr. Seeto will continue to provide transition consulting services to the Company.
On July 8, 2018, the Company and Dr. Seeto entered into a Transition and Separation Agreement (the Agreement) that, in exchange for a
general release of claims against the Company, provides for, among other things, a lump sum severance payment of approximately $417,000, and up to 12 months of premiums for continued health care coverage. The Agreement also provides for
Dr. Seeto to provide transition services as a consultant through as late as December 15, 2018, during which time Dr. Seetos equity awards will remain outstanding and continue to vest.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: July 9, 2018
|
|
|
|
ARDELYX, INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mark Kaufmann
|
|
|
|
|
|
|
|
|
Mark Kaufmann
|
|
|
|
|
|
|
|
|
Chief Financial Officer
|
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
From Apr 2023 to Apr 2024